Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
University of Washington · University of North Carolina at Chapel Hill · +3 more institutions
Abstract
A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic. We describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 SARS-CoV-2 spike receptor-binding domains (RBDs) in a highly immunogenic array and induce neutralizing antibody titers 10-fold higher than the prefusion-stabilized spike despite a 5-fold lower dose. Antibodies elicited by the RBD nanoparticles target multiple distinct epitopes, suggesting they may not be easily susceptible to escape mutations, and exhibit a lower binding:neutralizing ratio than convalescent human…
Citation impact
- FWCI
- 10.45
- Percentile
- 100%
- References
- 123
Authors
42Topics & keywords
- Neutralizing antibody
- Antibody
- Virology
- Epitope
- Biology
- Spike Protein
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Antigen
- Good health and well-being
Funding
- BWBurroughs Wellcome Fund
- BABill and Melinda Gates FoundationAwards: OPP1156262, OPP1126258, OPP1159947
- UOUniversity of WashingtonAwards: P51 OD010425, UWPR95794
- FGFast Grants
- NCNorth Carolina General Assembly
- NINational Institutes of HealthAwards: R01GM099989, -0001, R01GM120553, HHSN272201700036I, OD010425, P51 OD010425/OD/NIH HHS/United States, OPP1156262, P51 OD010425, HHSN272201700059C
- DTDefense Threat Reduction AgencyAwards: HDTRA1-18, HDTRA1-18-1-0001, HDTRA1
- UOUniversity of North Carolina at Chapel Hill
- NINational Institute of General Medical SciencesAward: R01GM120553
- NINational Institute of Allergy and Infectious DiseasesAwards: HHSN272201700059C, 75N93020F00001, DP1AI158186, HHSN272201700036I, OPP1156262